Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the pyrazole carboxamide class. It features a pyrazole ring substituted with a difluorobenzoyl group and a piperidine moiety. The drug acts as an inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CDK1, CDK2, and CDK17. By inhibiting these kinases—key regulators of cell cycle progression—it may modulate cellular proliferation and has potential applications in cancer research or other proliferative diseases. The compound is primarily used experimentally as a chemical probe for kinase inhibition studies[1][2][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide.